iBio (IBIO) Notes Payables (2011 - 2025)
iBio's (IBIO) quarterly Notes Payables came in at $706000.0 in Q3 2025, up 211.01% year-on-year from $227000.0 in Q3 2024, and down 7.83% on a QoQ basis from $766000.0 in Q2 2025.
iBio (IBIO) Notes Payables (2011 - 2025) Analysis & Trends
iBio (IBIO) has 9 years of Notes Payables data on file, last reported at $706000.0 in Q3 2025.
- On a quarterly basis, Notes Payables rose 211.01% year-over-year to $706000.0 in Q3 2025; TTM through Sep 2025 was $706000.0, a 211.01% increase from a year earlier, with the FY2025 full-year figure at $766000.0, up 522.76% from the prior year.
- Notes Payables for Q3 2025 stood at $706000.0, down from $766000.0 in the prior quarter.
- Over the last five years, Notes Payables for IBIO reached as high as $22.2 million in Q3 2022 and fell as low as $123000.0 in Q2 2024.
- Historically, Notes Payables has averaged $8.0 million across 5 years, with a median of $6.7 million in 2023.
- Across the five-year window, Notes Payables surged 3593.5% in 2022 and plunged 99.05% in 2024, its largest moves.
- Year by year, Notes Payables stood at $600000.0 in 2021, then soared by 2568.5% to $16.0 million in 2022, then slipped by 20.96% to $12.7 million in 2023, then slumped by 98.13% to $237000.0 in 2024, then jumped by 197.89% to $706000.0 in 2025.
- Per Business Quant data, the three most recent Notes Payables figures were $706000.0 in Q3 2025, $766000.0 in Q2 2025, and $455000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - |
| 2 | Nanobiotix | 1,913.26 Bn | 1,913.20 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.02 Bn | 466.23 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.17 Bn | 114.92 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.10 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.60 Bn | 50.42 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.39 Bn | 34.38 Bn | 959.66 Mn |
| 10 | iBio | 174.62 Mn | 174.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 706,000.00 |
| Jun 30, 2025 | 766,000.00 |
| Mar 31, 2025 | 455,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Jun 30, 2024 | 123,000.00 |
| Mar 31, 2024 | 12.66 Mn |
| Dec 31, 2023 | 12.66 Mn |
| Sep 30, 2023 | 12.63 Mn |
| Jun 30, 2023 | 12.94 Mn |
| Mar 31, 2023 | 13.70 Mn |
| Dec 31, 2022 | 16.01 Mn |
| Sep 30, 2022 | 22.20 Mn |
| Jun 30, 2022 | 22.16 Mn |
| Jun 30, 2021 | 600,000.00 |
| Mar 31, 2021 | 566,000.00 |
| Dec 31, 2020 | 465,000.00 |
| Sep 30, 2020 | 362,000.00 |
| Jun 30, 2020 | 261,000.00 |
| Mar 31, 2020 | 1.20 Mn |